Differential Gene Regulation by PPAR
Agonist and Constitutively Active PPAR
2
Yong Li and
Mitchell A. Lazar
Division of Endocrinology, Diabetes, and Metabolism, Departments of Medicine and Genetics, and The Penn Diabetes Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104
Address all correspondence and requests for reprints to: Mitchell A. Lazar, M.D., Ph.D., University of Pennsylvania School of Medicine, 611 Clinical Research Building, 415 Curie Boulevard, Philadelphia, Pennsylvania 19104-6149. E-mail: lazar{at}mail.med.upenn.edu.
 |
ABSTRACT
|
---|
The PPAR
is a key adipogenic determination factor. Ligands for PPAR
such as antidiabetic thiazolidinedione (TZD) compounds are adipogenic, and many adipocyte genes that are activated by TZDs contain binding sites for PPAR
. Like ligands for other nuclear receptors, TZDs can regulate genes positively or negatively. Here, we sought to understand the importance of positive regulation of gene expression by PPAR
in adipogenesis. Fusion of the potent viral transcriptional activator VP16 to PPAR
2 (VP16-PPAR
) created a transcription factor that constitutively and dramatically activated transcription of PPAR
-responsive genes in the absence of ligand. Forced expression of VP16-PPAR
in 3T3-L1 preadipocytes using retroviral vectors led to adipogenesis in the absence of standard differentiating medium or any exogenous PPAR
ligand. Gene microarray analysis revealed that VP16-PPAR
induced many of the genes associated with adipogenesis and adipocyte function. Thus, direct up-regulation of gene expression by PPAR
is sufficient for adipogenesis. TZD-induced adipogenesis up-regulated many of the same genes, although some were divergently regulated, including resistin, whose gene expression was reduced inVP16-PPAR
adipocytes treated with TZDs. These results show that, although activation of PPAR
by a heterologous activation domain is sufficient for adipogenesis, it is not equivalent to TZD treatment. This conclusion has important implications for understanding biological effects of the TZDs on adipogenesis and insulin sensitization.
 |
INTRODUCTION
|
---|
THE NUCLEAR RECEPTOR PPAR
is expressed at highest level in adipose tissue and is a key transcription factor involved in adipocyte differentiation (1, 2). Thiazolidinedione (TZD) ligands that have been shown to bind and activate PPAR
(3) are currently used in the treatment of type 2 diabetes in humans (4). Like other PPAR
ligands, TZDs are adipogenic (5, 6, 7, 8). Many adipocyte genes that are activated by TZDs, such as the adipocyte-specific aP2 gene, contain binding sites for PPAR
(9). PPAR
is required for adipose development in vivo and in cultured cells (10, 11, 12). Interestingly, mice with heterozygous loss of the PPAR
gene showed improved insulin sensitivity (11, 13).
Positive regulation by nuclear receptors, including PPAR
, involves a fairly well understood exchange of corepressors and coactivators leading to induction of receptor-bound genes (14). TZDs, like other nuclear receptor ligands, can regulate genes negatively as well as positively. Negative regulation is much less well understood and may involve positive regulation of a repressor protein (15), direct DNA binding (16), binding to other transcription factors (17), as well as competition for coactivators in solution off DNA (18).
TZDs function as potent insulin sensitizing agents in vivo despite the fact that they increase body weight (19), and increased adiposity is associated with insulin resistance (20). This suggests that some adipocyte genes whose expression is altered during adipogenesis might be differentially regulated by TZDs. In adipocytes, the secreted hormone resistin is an example of a gene that is up-regulated during adipogenesis but down-regulated by TZDs (21, 22). Like other examples of negative regulation by TZDs, the mechanism of resistin down-regulation of is not well understood. Clearly, however, it cannot be identical to the marked up-regulation of the resistin gene that is observed during adipogenesis (21, 23).
Here we sought to understand the importance of positive and negative regulation of gene expression by PPAR
and its ligands in adipogenesis. We found that the fusion of the potent viral transcriptional activator VP16 to PPAR
2 (VP16-PPAR
) created a transcription factor that constitutively and dramatically activated transcription of PPAR
-responsive genes in the absence of ligand. Like nuclear receptor coactivators, VP16 positively regulates transcription by increasing histone acetylation and remodeling the chromatin environment of genes to which it is recruited (24). VP16-PPAR
is thus a model for positive regulation of target genes that are bound directly by PPAR
. Forced expression of VP16-PPAR
in 3T3-L1 preadipocytes using retroviral vectors led to adipogenesis in the absence of standard differentiating medium (DM) or any exogenous PPAR
ligand. Gene microarray analysis revealed that VP16-PPAR
induced many adipocyte genes. However, despite the presence of activated PPAR
in the cells, TZD treatment markedly down-regulated resistin gene expression in VP16-PPAR
adipocytes. These results show that constitutively active PPAR
is sufficient for adipogenesis and that TZD treatment is not equivalent to activation of PPAR
in adipocytes.
 |
RESULTS
|
---|
VP16-PPAR
Constitutively Activates Transcription of PPAR
-Responsive Genes in the Absence of Ligand
To create a transcription factor that constitutively activates PPAR
-responsive genes in the absence of ligand, the potent viral transcriptional activator VP16 was fused to PPAR
2 (VP16-PPAR
). To compare the transcriptional activity of VP16-PPAR
and ligand-activated PPAR
, the plasmid VP16-PPAR
and a PPAR response reporter were transiently transfected into 293T cells and studied in the presence or absence of a potent TZD, rosiglitazone. As expected, rosiglitazone markedly activated transcription (3- to 4-fold) in the presence of cotransfected PPAR
(Fig. 1
). Transcriptional activation by VP16-PPAR
was dramatically greater (over 100-fold), even in the absence of rosiglitazone. Moreover, the PPAR
ligand had no further effect on the transcriptional activity of VP16-PPAR
. These results indicate that VP16-PPAR
is a potent activator of positively regulated PPAR
-responsive genes.
Expression of VP16-PPAR
in 3T3-L1 Cells Induces Adipocyte Differentiation in the Absence PPAR
Ligand
Rosiglitazone induces adipocyte differentiation of preadipocytic 3T3-L1 cells, most likely by activating low levels of PPAR
, which is autoinduced during adipogenesis (25). By contrast, forced expression of wild-type PPAR
is only weakly adipogenic in the absence of ligand (7, 26). To determine the effect of constitutive activation of positively regulated PPAR
target genes, VP16-PPAR
was expressed from a retroviral vector in 3T3-L1 preadipocytes as we have previously described for wild-type PPAR
, as well as C/EBP
and C/EBPß (25, 27, 28). Notably, expression of VP16-PPAR
led to adipogenesis in the absence of standard DM or any exogenous PPAR
ligand, as indicated by Oil Red O staining (Fig. 2a
). The extent of differentiation was similar to that observed with rosiglitzone treatment. As expected (25, 27, 28), both DM and rosiglitazone also induced the adipogenic bZip transcription factor C/EBP
(Fig. 2b
). VP16-PPAR
induced the expression of C/EBP
to a similar extent, but in a manner that was independent of external adipogenic stimulus (Fig. 2b
). Note that both the larger and smaller forms of C/EBP
, respectively known as LAP and LIP, were induced by VP16-PPAR
. As in differentiation by DM or TZD treatment, the induction of C/EBP
is likely to contribute to the adipogenic effects of VP16-PPAR
expression.
We also performed microarray analysis to compare gene expression in 3T3-L1 cells infected with control retrovirus (LXSN) and with the VP16-PPAR
retrovirus. The arrays contained probe sets for about 6,000 known genes, representing about 1020% of the total number in the genome. Seventy-eight genes were increased greater than 3-fold in the VP16-PPAR
3T3-L1 cells, whereas only 28 were down-regulated more than 3-fold. The high proportion of induced genes is consistent with the strong activational nature of the VP16-PPAR
protein. Negatively regulated genes are likely to be regulated indirectly, either as a consequence of primary gene activation or due to squelching of positive cofactors. The list of induced genes includes many that are characteristic of adipogenesis and the adipocyte phenotype, including adipogenic transcription factors (PPAR
, C/EBP
), adipose-specific secreted proteins (resistin, adipsin, adiponectin/Acrp30), and adipocyte metabolic genes (glycerol phosphate dehydrogenase, pyruvate carboxylase, hormone sensitive lipase, steroyl coenzyme A desaturase I, fatty acid coenzyme A synthase, fatty acid synthase) (Table 1
). Thus, the 3T3-L1 cells expressing VP16-PPAR
are bona fide adipocytes by many criteria.
Differential Gene Regulation in Adipogenesis Induced by VP16-PPAR
and PPAR
Ligand
The above results show that many genes induced by VP16-PPAR
were previously known to be adipocyte genes, consistent with the phenotype of the VP16-PPAR
cells. TZDs also induce adipocyte differentiation but might regulate a different set of genes because TZDs can negatively regulate gene expression via PPAR
(29) and may have effects that are independent of PPAR
(30). 3T3-L1 cells were infected with control LXSN retrovirus, then cultured in the presence of rosiglitazone. This experiment was performed at the same time as the VP16-PPAR
infection, and the cells underwent adipogenesis to similar extents (see Fig. 2
). Microarray analysis of the same gene set as described above was performed, and many of the same adipocyte genes induced by VP16-PPAR
were also induced by treatment with rosiglitazone, although not always to the same extent (see Table 1
). Northern analysis for aP2 and PPAR
, two adipocyte-predominant genes found to be induced by microarray analysis of VP16-PPAR
cells, showed that both are induced by VP16-PPAR expression to levels comparable to that due to treatment with rosiglitazone and standard differentiating conditions (Fig. 3
, compare lane 4 with lanes 2 and 3).
The VP16-PPAR
cells were compared with the rosiglitazone-treated, LXSN control cells. Overall, many fewer genes were differentially regulated more than 3-fold by rosiglitazone-induced differentiation as compared with differentiation due to constitutively activated PPAR
. Moreover, only eight genes were induced at least 3-fold greater by rosiglitazone than in the VP16-PPAR
cells. The most differentially regulated gene in this category was the mammalian homolog of the yeast secretory pathway protein Sec53p, whose expression was 11.3-fold greater in the microarray analysis of cells induced by rosiglitazone. Northern analysis confirmed that this gene is induced by rosiglitazone, but not by VP16-PPAR
, suggesting that the TZD may activate this gene independent of PPAR
(Fig. 4
, compare lanes 2 and 5 with each other and with lanes 1 and 4, respectively). By contrast, a much greater number of genes were found to be down-regulated at least 3-fold in the rosiglitazone-differentiated LXSN cells relative to the cells differentiated by VP16-PPAR
in the absence of ligand. The most differentially regulated gene in this category was the IGF-II gene, whose expression was 30-fold lower in microarray comparison of the rosiglitazone-induced cells and the VP16-PPAR
cells. Northern analysis confirmed the lower expression in rosiglitazone-treated cells (Fig. 4
, lanes 2 and 5). Interestingly, IGF-II was also expressed at similar levels in the preadipocytes as in the VP16-PPAR
expressing cells (lanes 1 and 4), suggesting that activated PPAR
is not responsible for the high (but comparable) expression. Consistent with this, rosiglitazone down-regulated IGF-II gene expression in the VP16-PPAR
2 cells as well as in the undifferentiated cells.

View larger version (64K):
[in this window]
[in a new window]
|
Figure 4. Resistin Is Induced during VP16-PPAR -Mediated Adipogenesis, but Down-Regulated by TZDs
Cells were treated as in Fig. 3 , and probed for resistin gene expression. Ethidium bromide staining of rRNA is shown as evidence of equal loading.
|
|
Resistin Is Down-Regulated by Rosiglitazone in VP16-PPAR
Adipocytes
Another gene whose expression was lower in rosiglitazone-differentiated adipocytes than in VP16-PPAR
adipocytes was resistin, whose expression was 3.6-fold higher in the VP16-PPAR
adipocytes. Resistin is an adipocyte-secreted hormone that is known to be up-regulated during adipogenesis (21, 23). Resistin was the most highly induced gene in our microarray profile of VP16-PPAR
adipocytes (144-fold; see Table 1
). Resistin is also known to be down-regulated by TZDs in 3T3-L1 cells (21), although the molecular mechanism by which TZDs down-regulate resistin is not known. Multiple TZDs down-regulate resistin expression in adipocytes, with a dose-response profiles that parallel their ability to bind PPAR
(Refs. 21 and 23 ; and data not shown). The dramatic induction of resistin in the VP16-PPAR
cell adipogenesis was confirmed by Northern analysis, and comparable to the induction of resistin during adipocytic differentiation of control cells with DM (Fig. 4
). These data strongly suggest that transcriptional activation of PPAR
activates resistin expression, either directly or indirectly, the latter by initiating the adipogenic cascade. Consistent with the microarray analysis, resistin gene induction was much less during rosiglitazone-induced adipogenesis (Fig. 4
, compare lanes 2 and 3). Importantly, the combination of rosiglitazone treatment and forced expression of VP16-PPAR
led to resistin expression at approximately the level of the control cells differentiated with rosiglitazone, and much lower than that in the VP16-PPAR
cells (compare lanes 4 and 5). This contrasts with the effect on other adipose genes including PPAR
and aP2, which were not decreased by the combination of VP16-PPAR
expression and rosiglitazone (see Fig. 3
).
The preceding experiments compared the effects of rosiglitazone and VP16-PPAR
expression in the context of conversion of preadipocytes to adipocytes. We next investigated the effects of rosiglitazone on resistin expression in the differentiated VP16-PPAR
adipocytes. If the effect of TZDs was solely to activate PPAR
, and if the induction of resistin in the VP16-PPAR
cells was due to direct activation of the resistin promoter, then TZD treatment should not decrease resistin expression. By contrast, rosiglitazone markedly reduced resistin gene expression in the VP16-PPAR
adipocytes (Fig. 5
). This suggests that this effect of rosiglitazone was not due to activation of PPAR
and dramatically illustrates a molecular distinction between the effect of rosiglitazone and activation of PPAR
by a heterologous transcriptional activation domain.

View larger version (55K):
[in this window]
[in a new window]
|
Figure 5. Down-Regulation of Resistin Expression in VP16-PPAR Adipocytes by TZDs
3T3-L1 cells were differentiated using VP16-PPAR , then d 7 adipocytes (D7) were treated with 1 µM rosiglitazone or vehicle for 48 h. Ethidium bromide staining of rRNA is shown as evidence of equal loading.
|
|
 |
DISCUSSION
|
---|
We have shown that a constitutively active form of PPAR
is sufficient for adipogenesis. The similarities between 3T3-L1 adipocytes treated with DM or rosiglitazone and those ectopically expressing constitutively activation of PPAR
are striking. Adipocyte differentiation was induced to similar extents, and many of the same adipocyte genes were induced in all manipulations. In VP16-PPAR
, the viral coactivator functions by recruiting coactivator complexes including histone acetyltrasferases to the vicinity of PPAR
-bound genes (31). This strongly supports the notion that gene induction and adipogenesis due to TZDs are directly related to that the role of ligand in coactivator recruitment to PPAR
binding sites. This also indicates that activation of gene transcription by PPAR
is sufficient for adipogenesis.
A number of genes were noted to be down-regulated during adipogenesis due to VP16-PPAR
. There are a number of potential explanations for this. Given the role of VP16 as an activator, we favor the possibility such effects involve induction of one or more repressor proteins. VP16-PPAR
could also down-regulate the expression certain genes by transrepression due to squelching of coactivators such as p300/CBP (18). It is also possible that the mechanism of negative regulation by VP16-PPAR
would be identical to that of transrepression by TZD binding to PPAR
. This, however, seems unlikely because the latter requires the charge clamp that mediates ligand-dependent interactions with proteins containing LXXLL motifs. (29).
Although VP16-PPAR
expression and TZD treatment both triggered adipogenesis, TZDs clearly regulated some genes differently than transcriptional activation of PPAR
-RXR, as accomplished by VP16-PPAR
. A number of mechanisms are likely to contribute to the difference between constitutive and ligand activation of PPAR
. First, although both VP16-PPAR
and rosiglitazone-bound PPAR
recruit many of the same coactivators containing histone acetyltrasferase activity, such as CBP/p300 (32) and the activated-recruited cofactor/VDR interacting protein/TR-associated protein complex (33, 34, 35), coactivators may be recruited with different affinities and potencies in terms of gene activation. This point is emphasized by the striking ability of VP16-PPAR
to activate a PPRE-containing reporter nearly 100-fold better than rosiglitazone-bound PPAR
(Fig. 1
). Yet, although rosiglitazone did not further activate the PPRE-containing reporter, it did enhance activation of the endogenous aP2 gene in adipocytes expressing VP16-PPAR
(Fig. 3
). This is consistent with previous observations that the magnitude of activation of the aP2 promoter varies among coactivators of different classes (36). The p160 class of coactivators are relatively specific for the nuclear receptor superfamily (37). Even among nuclear receptors, different ligand-bound receptors may prefer one class of coactivators over another. PPAR
prefers CBP to the p160 coactivator, whereas its heterodimer partner RXR prefers the p160 coactivator in the same complex (38, 39). PPAR
also binds corepressors nuclear receptor corepressor/silencing mediator for RA and TRs, and it is likely that the binding is different for VP16-PPAR
than for PPAR
bound to rosiglitazone (40, 41). It is also possible that rosiglitazone functions as a partial agonist of PPAR
on a subset of target genes, as has been described for other TZDs including troglitazone (42) and MCC-555 (43) as well as non-TZD PPAR
ligands (44), By contrast, VP16-PPAR
would be expected to be a pure transcriptional activator. In addition, TZD binding to PPAR
transrepresses certain genes in a manner that would not be expected for VP16-PPAR
because, as noted before, this function requires ligand and the charge clamp that mediates interactions with LXXLL containing proteins such as the p160 coactivators (29).
Relatively few genes are established as being differentially regulated by TZD treatment and by adipogenesis per se. One gene that is strongly induced in adipocytes by TZDs encodes Cbl-associated protein (45), which plays important roles in insulin-stimulated glucose transport (46). The present study shows that the Sec53 protein is also induced in adipocytes by rosiglitazone. Conversely, IGF-II gene expression is altered significantly by adipocyte differentiation but is down-regulated by TZD treatment. The functions of Sec53 and IGF-II in TZD actions apart from adipoogenesis remain to be elucidated.
Resistin induction during adipogenesis occurs with all inducers, but it is dramatically greater with DM or VP16-PPAR
than with rosiglitazone. Negative regulation of resistin gene expression by TZD could be mediated via a PPAR
binding site on the resistin gene, such that constitutively activated PPAR
would paradoxically induce resistin expression. Arguing against this, TZD treatment of VP16-PPAR
cells either during adipogenesis or as mature adipocytes led to reduction of resistin gene expression. It is also unlikely that activated PPAR
induces a repressor of resistin gene expression because resistin was dramatically up-regulated by VP16-PPAR
. Down-regulation of resistin gene expression by TZD could be by an off DNA mechanism involving PPAR
, such as squelching of limiting coactivators (18), or could even be independent of PPAR
. TZDs have been suggested to have PPAR
-independent effects on muscle (47), and recent studies of PPAR
null cells differentiated into macrophages suggests that negative regulation of cytokine gene expression by TZDs in that system may be independent of PPAR
(30). Unlike macrophages, PPAR
is required for adipocyte differentiation, making it impossible for us to study the effects of TZDs on resistin expression in PPAR
null adipocytes at this time (48, 49). Thus, we cannot draw any conclusion about whether PPAR
mediates the transrepressive effects of TZD that are not mimicked by VP16-PPAR
in adipocytes.
The induction of resistin may well be an indirect consequence of adipogenesis. Indeed, resistin is induced during TZD-induced adipogenesis, albeit markedly (3.6-fold) less than with VP16-PPAR
, which is comparable to DM (Fig. 4
). Thus, resistin might be increased by TZD in vivo under circumstances where de novo adipogenesis is dominant over metabolic effects on mature adipocytes, where resistin expression is reduced. These characteristics of resistin gene expression could explain why some studies have found that rosigliatzone treatment of mice down-regulates resistin gene expression (21, 50), whereas another noted up-regulation of the resistin gene with PPAR
ligands (51).
Thus, our work shows that constitutively active PPAR
is sufficient for adipogenesis, but points out that gene regulation during this process is not identical to that during adipocyte differentiation stimulated by PPAR
ligand. Intriguingly, a PPAR
antagonist that blocks TZD-induced adipocyte differentiation does not inhibit adipogenesis by DM (52). This suggests that, as with VP16-PPAR
, the adipogenic stimulus of DM can be distinguished from the effects of TZDs. It remains to be determined whether genes regulated by TZD but not by adipogenesis per se or by VP16-PPAR
are mechanistically related to the insulin-sensitizing effects of these compounds.
 |
MATERIALS AND METHODS
|
---|
Cell Culture and Differentiation
3T3-L1 preadipocytes were maintained in growth media containing 10% FBS and differentiated as described previously (25). Briefly, for standard adipocyte differentiation, 2 d after cells reached confluency (referred as d 0), cells were exposed to DM containing 10% FBS for 48 h, then were maintained in postdifferentiation medium containing 10% FBS. For BRL 49653-induced adipogenesis, 1 µM BRL 49653 was added to post-confluent cells for 710 d until fat cells were seen. The cDNA of VP16 fused with full-length PPAR
was ligated into retroviral vector LXSN. Ectopically expressing cells were made as described before (25).
Transient Transfection Transcription Assay
Cell Culture and Transient Transfection.
293T cells were maintained in DMEM with high glucose supplemented with 10% FBS (Life Technologies, Inc., Gaithersburg, MD) and grown at 37 C in 5% CO2. Cells were transiently transfected using lipofectamine (Life Technologies, Inc.) according to the manufacturers directions. Ligands were added 16 h after transfection, and cells were harvested 24 h later. The results were normalized to transfection efficiency as determined by ß-galactosidase expression, as described previously (53).
Oil Red O Staining
3T3-L1 cells were washed three times with PBS, fixed by 10% formalin in phosphate buffer for 1 h, and washed again with PBS. The cells were then stained with a filtered Oil Red O stock solution [0.5 g of Oil Red O (Sigma, St. Louis, MO) in 100 ml of isopropyl alcohol] for 15 min at room temperature, then washed twice with water for 15 min each and visualized.
Western Analysis
3T3-L1 cells were washed in PBS and lysed with NET-N buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl at pH 8.0, 0.5% Nonidet P-40, and 10% glycerol) containing protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN) on ice for 30 min, followed by centrifugation at 17,000 rpm at 4 C for 30 min. Supernatant was collected, and protein concentration was determined by Bio-Rad Laboratories, Inc. (Hercules, CA) protein assay. Sixty micrograms of protein were subjected to 10% polyacrylamide gel electrophoresis. Proteins were then transferred to nitrocellulose membrane. The membrane was incubated first with primary antibody [anti-PPAR, 1:1500 (23); anti-C/EBP, 1:300 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)] for 2 h, followed by secondary antibody (horseradish peroxidase conjugated) for 1 h. Blots were developed using ECL chemiluminescence detection reagent (Amersham Pharmacia Biotech, Inc., Arlington Heights, IL) and visualized by exposure to autoradiography film.
Northern Blotting and Microarray Analysis
Total RNA was extracted from 3T3-L1 cells with Trizol reagent (Life Technologies, Inc.) and Northern analysis were performed as described previously (54). Biotin-labeled cRNA was prepared according to the Affymetrix (Santa Clara, CA) expression analysis technical manual. Hybridization to Murine Genome U74A arrays was performed at the Research Genetics, Inc. (Huntsville, AL).
 |
ACKNOWLEDGMENTS
|
---|
We thank Hong-Ping Guan for valuable discussions and for comments on the manuscript.
 |
FOOTNOTES
|
---|
This work was supported by Grants DK-49780 and DK-49210 from the NIDDK (to M.A.L.).
Abbreviations: DM, Differentiation medium; LXSN, 3T3-L1 cells infected with control retrovirus; TZD, thiazolidinedione; VP16, potent viral transcriptional activator.
Received for publication September 26, 2001.
Accepted for publication January 17, 2002.
 |
REFERENCES
|
---|
-
Rosen ED, Spiegelman BM 2000 Transcriptional regulation of adipogenesis. Genes Dev 14:12931307[Free Full Text]
-
Rangwala SM, Lazar MA 2000 Transcriptional control of adipogenesis. Annu Rev Nutr 8:535559
-
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA 1995 An antidiabetic thiazolidinedione is a high affinity ligand for the nuclear peroxisome proliferator-activated receptor
(PPAR
). J Biol Chem 270:1295312956[Abstract/Free Full Text]
-
Olefsky JM, Saltiel AR 2000 PPAR
and the treatment of insulin resistance. Trends Endocrinol Metab 11:362368[CrossRef][Medline]
-
Kletzien RF, Clarke SD, Ulrich RG 1992 Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41:393398[Abstract]
-
Chawla A, Lazar MA 1994 Peroxisome proliferator and retinoid signalling pathways coregulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 91:17861790[Abstract]
-
Tontonoz P, Hu E, Spiegelman BM 1994 Stimulation of adipogenesis in fibroblasts by PPAR
2, a lipid-activated transcription factor. Cell 79:11471156[Medline]
-
Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-deoxy,
12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR
. Cell 83:803812[Medline]
-
Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM 1994 mPPAR
2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:12241234[Abstract]
-
Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM 1999 PPAR
is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585595[Medline]
-
Kubota N, Terauchi T, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T 1999 PPAR
mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597609[Medline]
-
Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM 1999 PPAR
is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611617[Medline]
-
Miles PD, Barak Y, He W, Evans RM, Olefsky JM 2000 Improved insulin-sensitivity in mice heterozygous for PPAR-
deficiency. J Clin Invest 105:287292[Abstract/Free Full Text]
-
Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121141[Free Full Text]
-
Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ 2000 Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507515[Medline]
-
Sasaki S, Lesoon-Wood LA, Dey A, Kuwata T, Weintraub BD, Humphrey G, Yang WM, Seto E, Yen PM, Howard BH, Ozato K 1999 Ligand-induced recruitment of a histone deacetylase in the negative-feedback regulation of thyrotropin beta gene. EMBO J 18:53895398[Abstract/Free Full Text]
-
Nissen RM, Yamamoto KR 2000 The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14:23142329[Abstract/Free Full Text]
-
Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S-C, Heyman RA, Rose DW, Glass CK, Rosenfeld MG 1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403414[Medline]
-
Mauvais-Jarvis F, Andreelli F, Hanaire-Broutin H, Charbonnel B, Girard J 2001 Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights. Diabetes Metab 27:41523[Medline]
-
Kopelman PG 2000 Obesity as a medical problem. Nature 404:6356453[Medline]
-
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409:307312[CrossRef][Medline]
-
Haugen F, Jorgensen A, Drevon CA, Trayhurn P 2001 Inhibition by insulin of resistin gene expression in 3T3L1 adipocytes. FEBS Lett 507:105108[CrossRef][Medline]
-
Kim KH, Lee K, Moon YS, Sul HS 2001 A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276:1125211256[Abstract/Free Full Text]
-
Utley RT, Ikeda K, Grant PA, Cote J, Steger DJ, Eberharter A, John S, Workman JL 1998 Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature 394:498502[CrossRef][Medline]
-
Shao D, Lazar MA 1997 PPAR
, C/EBP
, cell cycle status and the commitment to adipocyte differentiation. J Biol Chem 272:2147321478[Abstract/Free Full Text]
-
Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA 1998 Interdomain communication regulating PPAR
ligand binding. Nature 396:377380[CrossRef][Medline]
-
El-Jack AK, Hamm JK, Pilch PF, Farmer SR 1999 Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPAR
and C/EBP
. J Biol Chem 274:79467951[Abstract/Free Full Text]
-
Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C, Darlington GJ, Spiegelman BM 1999 Cross-regulation of C/EBP
and PPAR
controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 3:151158[Medline]
-
Li M, Pascual G, Glass CK 2000 Peroxisome proliferator-activated receptor
-dependent repression of the nitric oxide synthase gene. Mol Cell Biol 20:46994707[Abstract/Free Full Text]
-
Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM 2001 PPAR-
dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:4852[CrossRef][Medline]
-
Naar AM, Lemon BD, Tjian R 2001 Transcriptional Coactivator Complexes. Annu Rev Biochem 70:475501[CrossRef][Medline]
-
Naar AM, Boutin J-M, Lipkin SM, Yu VC, Holloway JM, Glass CK, Rosenfeld MG 1991 The orientation and spacing of core DNA-binding motif dictate selective transcriptional responses to three nuclear receptors. Cell 65:12671279[Medline]
-
Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar A, Erdjument-Bromage H, Tempst P, Freedman LP 1999 Nuclear receptors require the DRIP complex for ligand-dependent transactivation on chromatin complexes in vitro. Nature 398:824828[CrossRef][Medline]
-
Naar AM, Beaurang PA, Zhou S, Abraham S, Solomon W, Tjian R 1999 Composite co-activator ARC mediates chromatin-directed transcriptional activation. Nature 398:828832[CrossRef][Medline]
-
Ito M, Yuan CX, Malik S, Gu W, Fondell JD, Yamamyra S, Fu ZY, Zhang X, Qin J, Roeder RG 1999 Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 3:361370[Medline]
-
Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM 1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829839[Medline]
-
McKenna NJ, Lanz RB, OMalley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321344[Abstract/Free Full Text]
-
Schulman IG, Shao G, Heyman RA 1998 Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor
(PPAR
) heterodimers: intermolecular synerty requires only the PPAR
hormone-dependent activation function. Mol Cell Biol 18:34833494[Abstract/Free Full Text]
-
Yang W, Rachez C, Freedman LP 2000 Discrete roles for peroxisome proliferator-activated receptor
and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol 20:80088017[Abstract/Free Full Text]
-
Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK 2000 A dominant-negative peroxisome proliferator-activated receptor
(PPAR
) mutant is a constitutive repressor and inhibits PPAR
-mediated adipogenesis. J Biol Chem 275:57545759[Abstract/Free Full Text]
-
Lavinsky RM, Kristen J, Thorsten H, Torchia J, Mullen T-M, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne CK, Glass CK, Rosenfeld MG 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:29202925[Abstract/Free Full Text]
-
Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T 2000 Differential activation of peroxisome proliferator-activated receptor-
by troglitazone and rosiglitazone. Diabetes 49:539547[Abstract]
-
Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Takaka H 1998 A potent antidiabetic thiazolidinedione with unusual PPAR
-activating properties. J Biol Chem 273:3267932684[Abstract/Free Full Text]
-
Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde HA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM 1999 A peroxisome proliferator-activated receptor
ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 96:61026106[Abstract/Free Full Text]
-
Ribon V, Johnson JH, Camp HS, Saltiel AR 1998 Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor
activation stimulates expression of the CAP gene. Proc Natl Acad Sci USA 95:1475114756[Abstract/Free Full Text]
-
Baumann CA, Ribon V, Kanzaki M, Thurmond DC, Mora S, Shigematsu S, Bickel PE, Pessin JE, Saltiel AR 2000 CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407:202207[CrossRef][Medline]
-
Brunmair B, Gras F, Neschen S, Roden M, Wagner L, Waldhausl W, Furnsinn C 2001 Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-
-mediated changes in gene expression. Diabetes 50:23092315[Abstract/Free Full Text]
-
Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS 2002 PPAR
knockdown by engineered transcription factors: exogenous PPAR
2 but not PPAR
1 reactivates adipogenesis. Genes Dev 16:2732[Abstract/Free Full Text]
-
Rosen ED, Hsu C-H, Wang X, Sakai S, Freeman MW, Gonzalez FJ, Spiegelman BM 2002 C/EBP
induces adipogenesis through PPAR
: a unified pathway. Genes Dev 16:2226[Abstract/Free Full Text]
-
Moore GB, Chapman H, Holder JC, Lister CA, Piercy V, Smith SA, Clapham JC 2001 Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 286:735741[CrossRef][Medline]
-
Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver Jr WR, Willson TM, Kliewer SA, Hotamisligil GS 2001 Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor
agonists. J Biol Chem 276:2565125653[Abstract/Free Full Text]
-
Mukherjee R, Hener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti JR 2000 A selective peroxisome proliferator-activated receptor
modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3L1 adipocytes. Mol Endocrinol 14:14251433[Abstract/Free Full Text]
-
Schwarz EJ, Reginato MJ, Shao D, Krakow SL, Lazar MA 1997 Retinoic acid blocks adipogenesis by inhibiting C/EBPß-mediated transcription. Mol Cell Biol 17:15521561[Abstract]
-
Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA 1994 Peroxisome proliferator-activated receptor
(PPAR
): adipose predominant expression and induction early in adipocyte differentiation. Endocrinology 135:798800[Abstract]
-
Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, Spiegelman BM 1987 Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 237:402405[Medline]
-
Pairault J, Green H 1979 A study of the adipose conversion of suspended 3T3 cells by using glycerophosphate dehydrogenase as differentiation marker. Proc Natl Acad Sci USA 76:51385142[Abstract]
-
Spiegelman BM, Frank M, Green H 1983 Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J Biol Chem 258:1008310089[Abstract/Free Full Text]
-
Rubin CS, Lai E, Rosen OM 1977 Acquisition of increased hormone sensitivity during in vitro adipocyte development. Proc Natl Acad Sci USA 252:35543557
-
Zhang J, Xia WL, Ahmad F 1995 Regulation of pyruvate carboxylase in 3T3L1 cells. Biochem J 306:205210[Medline]
-
Kawamura M, Jensen DF, Wancewicz EV, Joy LL, Khoo JC, Steinberg D 1981 Hormone-sensitive lipase in differentiated 3T3L1 cells and its activation by cyclic AMP-dependent protein kinase. Proc Natl Acad Sci USA 78:732736[Abstract]
-
Hu E, Liang P, Spiegelman BM 1996 AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:1069710703[Abstract/Free Full Text]
-
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF 1995 A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:2674626749[Abstract/Free Full Text]
-
Christy RJ, Yang VW, Ntambi JM, Geiman DE, Landschulz WH, Friedman AD, Nakabeppu Y, Kelly TJ, Lane MD 1989 Differentiation-induced gene expression in 3T3L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev 3:13231335[Abstract]
-
Gargiulo CE, Stuhlsatz-Krouper SM, Schaffer JE 1999 Localization of adipocyte long-chain fatty acyl-CoA synthetase at the plasma membrane. J Lipid Res 40:881892[Abstract/Free Full Text]
-
Bernlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly TJ 1984 Expression of specific mRNAs during adipose differentiation: identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci USA 81:54685472[Abstract]
-
Hunt CR, Ro JH-S, Dobson DE, Min HY, Spiegelman BM 1986 Adipocyte P2 gene: developmental expression and homology of 5'-flanking sequences among fat cell-specific genes. Proc Natl Acad Sci USA 83:37863790[Abstract]
-
Saye JA, Cassis LA, Sturgill TW, Lynch KR, Peach MJ 1989 Angiotensinogen gene expression in 3T3L1 cells. Am J Physiol 256:C448C451
-
Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P 2001 LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98:507512[Abstract/Free Full Text]
-
Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusis AJ, Erickson SK, Farese Jr RV 1998 Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 95:1301813023[Abstract/Free Full Text]
-
Moldes M, Feve B, Pairault J 1999 Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage. differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase. J Biol Chem 274:95159523[Abstract/Free Full Text]
-
Paulauskis JD, Sul HS 1988 Cloning and expression of mouse fatty acid synthase and other specific mRNAs. Developmental and hormonal regulation in 3T3L1 cells. J Biol Chem 263:70497054[Abstract/Free Full Text]